Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Company profile
Ticker
NKTR
Exchange
Website
CEO
Howard Robin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INHALE THERAPEUTIC SYSTEMS, INHALE THERAPEUTIC SYSTEMS INC
SEC CIK
Corporate docs
Subsidiaries
Inheris Biopharma, Inc. ...
IRS number
943134940
NKTR stock data
News

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
1 Jul 22
Stocks That Hit 52-Week Lows On Monday
13 Jun 22
Expert Ratings for Nektar Therapeutics
31 May 22
Nektar Therapeutics's Return On Capital Employed Insights
31 May 22
Jefferies Assumes Nektar Therapeutics at Hold, Lowers Price Target of $4
31 May 22
Press releases
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
1 Jul 22
BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors
11 May 22
Nektar Therapeutics Reports First Quarter 2022 Financial Results
5 May 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
29 Apr 22
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
28 Apr 22
Analyst ratings and price targets
Current price
Average target
$5.00
Low target
$3.00
High target
$6.00
Mizuho
Maintains
$6.00
Goldman Sachs
Downgraded
$3.00
SVB Leerink
Maintains
$6.00
Investment data
Securities sold
Number of investors
Calendar
5 May 22
2 Jul 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 67.99M | 67.99M | 67.99M | 67.99M | 67.99M | 67.99M |
Cash burn (monthly) | (no burn) | 6.85M | 38.85M | 43.08M | 29.47M | 35.33M |
Cash used (since last report) | n/a | 20.99M | 119.08M | 132.03M | 90.33M | 108.29M |
Cash remaining | n/a | 47.01M | -51.08M | -64.04M | -22.34M | -40.3M |
Runway (months of cash) | n/a | 6.9 | -1.3 | -1.5 | -0.8 | -1.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 22 | John Northcott | Common Stock | Sell | Dispose S | No | No | 3.95 | 4,592 | 18.14K | 223,210 |
16 May 22 | Mark Andrew Wilson | Common Stock | Sell | Dispose S | No | No | 3.95 | 3,136 | 12.39K | 117,939 |
16 May 22 | Labrucherie Gil M | Common Stock | Sell | Dispose S | No | No | 3.95 | 17,448 | 68.92K | 312,905 |
16 May 22 | Robin Howard W | Common Stock | Sell | Dispose S | No | No | 3.95 | 36,529 | 144.29K | 620,941 |
16 May 22 | Thomsen Jillian B. | Common Stock | Sell | Dispose S | No | No | 3.95 | 5,841 | 23.07K | 170,427 |
15 May 22 | Labrucherie Gil M | Common Stock | Grant | Acquire A | No | No | 0 | 28,750 | 0 | 330,353 |
15 May 22 | Robin Howard W | Common Stock | Grant | Acquire A | No | No | 0 | 68,450 | 0 | 657,470 |
15 May 22 | Thomsen Jillian B. | Common Stock | Grant | Acquire A | No | No | 0 | 10,950 | 0 | 176,268 |
Institutional ownership, Q1 2022
93.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 239 |
Opened positions | 40 |
Closed positions | 43 |
Increased positions | 89 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 940.86M |
Total shares | 174.05M |
Total puts | 4.59M |
Total calls | 4.59M |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
IVZ Invesco | 37.23M | $200.67M |
BLK Blackrock | 26.11M | $140.76M |
Vanguard | 19.43M | $104.73M |
Primecap Management | 17.06M | $91.96M |
Wellington Management | 11.38M | $61.36M |
STT State Street | 5.8M | $31.26M |
BLVGF Bellevue | 4.81M | $25.92M |
Maverick Capital | 4.79M | $25.83M |
First Trust Advisors | 4.39M | $23.67M |
Camber Capital Management | 4M | $21.56M |
Financial report summary
?Competition
Pfizer • AMGEN • Caladrius Biosciences • Savient Pharmaceuticals • Celldex Therapeutics • Acura Pharmaceuticals • Celgene • Teva- Pharmaceutical Industries • Progenics Pharmaceuticals • Mosaic ImmunoEngineeringRisks
- We are highly dependent on the success of drug candidates, including NKTR-358 and NKTR-255. If these drug candidates fail in clinical development our business will be significantly harmed.
- Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.
- The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.
- The risk of clinical failure for any drug candidate remains high prior to regulatory approval and there can be no assurance that our product candidates will obtain regulatory approval.
- Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.
- Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.
- We are highly dependent on our collaboration partner to initiate, properly conduct and prioritize clinical trials for NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates.
- Our strategic reorganization plan and cost restructuring plan may not be successful.
- Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.
- We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.
- The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.
- If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.
- Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.
- If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.
- Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.
- We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.
- Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.
- If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.
- We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.
- Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.
- We depend on third parties to conduct the clinical trials for our biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.
- Our future depends on the proper management of our current and future business operations and their associated expenses.
- If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.
- Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.
- We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.
- If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.
- We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.
- We may not be able to obtain intellectual property licenses related to the development of our biologic candidates on a commercially reasonable basis, if at all.
- If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.
- We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.
- If product liability lawsuits are brought against us, we may incur substantial liabilities.
- If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.
- Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business.
- We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.
- If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.
- Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.
- The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action and shareholder derivative litigation.
- We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.
- We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.
- Changes in tax law could adversely affect our business and financial condition.
- The United Kingdom’s withdrawal from the EU may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.
- Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business.
- Our business could be negatively impacted by corporate citizenship and sustainability matters.
- If earthquakes or other catastrophic events strike, our business may be harmed.
Management Discussion
- Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
add, aforementioned, aim, aimed, anemia, antibody, Biolojic, bivalent, cancellation, certolizumab, Chron, conflict, consultation, core, discontinuation, discontinue, discontinued, duly, Erythropoietin, focused, GentiBio, insignificant, kidney, Kyverna, laid, leasehold, military, modification, modified, MOEVNTIG, naloxegol, NKTR, Omicron, pegol, PROPEL, reinstate, reorganization, restrain, retaliatory, revaluation, Russia, shipping, sublease, turnover, Ukraine, unrest, unstable, vendor, world
Removed:
abbreviated, Abingworth, abscopal, Adaptimmune, adult, advantage, Advisory, AG, aged, aggregated, agonist, alerting, amendment, analogized, Anaveon, Anesthetic, antagonist, antigen, antiviral, Apeiron, Apotex, applying, Armo, assign, assured, Aurobindo, automatically, axitinib, backed, Baxter, beginning, biology, biopharma, Blackstone, book, Breakthrough, Brooklyn, cabozantinib, capability, Celltech, charge, chimeric, cisplatin, clearance, clinic, clinically, collaborating, commandeered, communication, comprehensively, compromising, conform, convey, corroborated, creating, creditable, criterion, critically, customary, cytotoxic, dated, declaration, Declaratory, declared, deduct, deferred, demonstrated, dendritic, designation, deterioration, diagnosed, direction, disadvantage, discounted, Dohme, earliest, earned, educate, Emergency, emerging, encounter, equal, equaling, estimating, evidence, exclusive, expedited, exploring, faster, Finally, flexibility, Food, force, forecasted, frequent, futility, generation, Gilead, GlaxoSmithKline, GmbH, grow, holding, identical, immaterial, Immunotherapy, improvement, incorporating, individualized, ineligible, infection, infiltrating, infringed, inhibit, initially, insolvency, intensive, invalidity, invasive, IP, issuing, Japan, Kite, listed, maturation, medium, methodological, mild, mitigation, moderate, MSD, MSN, muscle, mutual, narrower, NDA, Neoleukin, nivolumab, November, NSCLC, observable, observed, older, Orange, outlined, Paragraph, pause, pediatric, Philogen, plc, preclude, prescribe, priming, priority, pro, promote, promotion, Pvt, qualify, qualifying, quoted, randomized, ranging, rata, RCC, reclassified, recommend, reconciliation, redhill, reflecting, regression, remained, repay, repayment, reserved, restricting, retained, robust, rolling, running, SA, Sanofi, science, secured, senior, served, Sharp, simultaneously, Society, standard, stipulation, strain, Sublicense, sublicensee, summer, supported, supporting, synergistic, Synthorx, Tesaro, theft, TIL, timeline, topline, trading, train, trend, tumor, underway, unenforceable, Unobservable, untreated, updated, USA, version, vi, virology, withdrew, wrote
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
1 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
8-K
Other Events
23 May 22
8-K
Nektar Therapeutics Reports First Quarter 2022 Financial Results
4 May 22
8-K
Cost Associated with Exit or Disposal Activities
2 May 22
8-K
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
25 Apr 22
8-K
Other Events
14 Apr 22
8-K
Other Events
14 Mar 22
8-K
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
28 Feb 22
8-K
Results of Operations and Financial Condition
11 Jan 22
Registration and prospectus
S-8
Registration of securities for employees
18 Aug 21
S-3ASR
Automatic shelf registration
12 Mar 21
S-8
Registration of securities for employees
7 Aug 20
S-8
Registration of securities for employees
29 Jun 18
D
$850M in equity, sold $850M, 1 investor
2 Apr 18
S-8
Registration of securities for employees
14 Jun 17
424B5
Prospectus supplement for primary offering
18 Oct 16
424B5
Prospectus supplement for primary offering
16 Oct 16
S-8
Registration of securities for employees
5 Aug 15
S-8
Registration of securities for employees
31 Jul 14
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
Other
UPLOAD
Letter from SEC
12 Dec 21
CORRESP
Correspondence with SEC
8 Nov 21
UPLOAD
Letter from SEC
25 Oct 21
UPLOAD
Letter from SEC
7 Feb 19
CORRESP
Correspondence with SEC
6 Dec 18
UPLOAD
Letter from SEC
18 Nov 18
CT ORDER
Confidential treatment order
22 May 18
UPLOAD
Letter from SEC
15 Jan 18
CORRESP
Correspondence with SEC
26 Dec 17
CT ORDER
Confidential treatment order
18 Dec 17
Ownership
4
NEKTAR THERAPEUTICS / Jonathan Zalevsky ownership change
17 May 22
4
NEKTAR THERAPEUTICS / Mark Andrew Wilson ownership change
17 May 22
4
NEKTAR THERAPEUTICS / Jillian B. Thomsen ownership change
17 May 22
4
NEKTAR THERAPEUTICS / HOWARD W ROBIN ownership change
17 May 22
4
NEKTAR THERAPEUTICS / JOHN NORTHCOTT ownership change
17 May 22
4
NEKTAR THERAPEUTICS / Gil M Labrucherie ownership change
17 May 22
4
NEKTAR THERAPEUTICS / Jonathan Zalevsky ownership change
18 Feb 22
4
NEKTAR THERAPEUTICS / Mark Andrew Wilson ownership change
18 Feb 22
4
NEKTAR THERAPEUTICS / Jillian B. Thomsen ownership change
18 Feb 22
4
NEKTAR THERAPEUTICS / HOWARD W ROBIN ownership change
18 Feb 22
Patents
Utility
Composition Comprising a Polymeric Reagent
12 May 22
The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates.
Utility
Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
3 May 22
Provided are methods and compositions directed towards the treatment of an individual having cancer by providing adoptive cell transfer therapy and administering to the individual a long-acting IL-2Rβ-biased agonist.
Utility
Multi-arm Polymer Prodrugs
17 Mar 22
Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same.
Utility
Polymeric Alpha-hydroxy Aldehyde and Ketone Reagents and Conjugation Method
17 Mar 22
Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction.
Utility
Oligomer-corticosteroid Conjugates
10 Mar 22
The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer.
Transcripts
2021 Q4
Earnings call transcript
1 Mar 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
6 Aug 21
2021 Q1
Earnings call transcript
7 May 21
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
7 Aug 20
2020 Q1
Earnings call transcript
8 May 20
2019 Q4
Earnings call transcript
28 Feb 20
2019 Q3
Earnings call transcript
6 Nov 19
Reddit threads
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Wall Street Week Ahead for the trading week beginning March 28th, 2022
25 Mar 22
Wall Street Week Ahead for the trading week beginning March 28th, 2022
25 Mar 22
Daily Discussion Thread - February 28th, 2022
28 Feb 22
Daily Discussion Thread - February 25th, 2022
25 Feb 22
Daily Discussion Thread - February 21st, 2022
21 Feb 22
Most Anticipated Earnings Releases for the week beginning February 21st, 2022
19 Feb 22
What are your top 3 bags you hold? Don’t you dare lie to me
31 Jan 22
Daily Discussion post - January 02 2022
2 Jan 22